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Abstract
To investigate the role of apoE in hepatic uptake of chylomi-
cron remnants, we studied chylomicron metabolism in trans-
genic mice overexpressing apoE in the liver. Plasma clearance
of injected "25I-labeled human chylomicrons was fivefold faster
in transgenic mice than in controls. Immunohistochemistry
demonstrated that apoE was specifically localized at the baso-
lateral surface of hepatocytes from fasted transgenic mice.
After injection ofa large amount ofchylomicrons, the density of
the cell surface apoE was markedly reduced and vesicular
staining was observed in the cytoplasm, suggesting that the cell
surface apoE was used for hepatic endocytosis of chylomicrons
and remnants. Polyacrylamide gel analysis ofchylomicrons and
remnants that had been reisolated from plasma and from liver
membrane after the injection ofchylomicrons showed the parti-
cles to be enriched with apoE mainly after their influx into the
liver rather than during their residence in plasma. These results
provide strong evidence for the secretion-recapture process of
apoE, whereby chylomicron remnants enter the sinusoidal
space, acquire apoE molecules, and subsequently are endocy-
tosed. Data from experiments with very low density lipoprotein
and LDL showed that this system is specific for chylomicron
remnants. (J. Clin. Invest. 1994. 93:2215-2223.) Key words:
apolipoprotein - chylomicron - lipoprotein - low density lipopro-
tein receptor - sinusoidal space
Introduction
ApoE is mainly produced in the liver and is a major constituent
ofmammalian lipoproteins. This protein, along with apoB 100,
plays a crucial role in the metabolism of plasma lipoproteins
mainly through its interaction with the LDL receptor in the
liver ( 1, 2). ApoE is also thought to be a specific ligand for a
putative hepatic chylomicron remnant receptor and to be in-
volved in the metabolism of intestinal lipoproteins ( 1, 2). Sev-
eral lines of evidence from both in vitro and in vivo studies
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1. Abbreviations used in this paper: LRP, low density lipoprotein recep-
tor-related protein.
suggest that lipoproteins containing several molecules ofapoE
have higher affinity for LDL receptors than those without apoE
(3-1 1 ). Recently, we established lines of transgenic mice with
high plasma levels of rat apoE, which is overproduced in the
liver under the control of the metallothionein promoter ( 12).
Homozygotes for line 4-20, the highest liver expressor, exhib-
ited a marked reduction in plasma cholesterol and triglyceride
levels, with elimination of VLDL and a marked decrease in
LDL ( 13). These decreases were caused by enhanced plasma
clearance of lipoproteins containing apoB, which were
enriched with apoE ( 13 ). Kinetic studies of plasma lipopro-
teins in these animals demonstrated that hepatic overexpres-
sion of apoE markedly enhances plasma turnover of VLDL
and LDL through interactions with LDL receptors and possi-
bly with LDL receptor-related proteins (LRP)' (14). We also
performed oral challenge with retinyl palmitate as a marker for
chylomicron remnant metabolism, and the data suggested that
hepatic overexpression of apoE markedly enhances clearance
ofchylomicron remnants ( 14). In contrast with VLDL, which
is produced in the liver, chylomicron particles are produced
and secreted by the intestine. In our transgenic line, apoE is
expressed in the liver and not in the intestine. The enhanced
clearance of chylomicron remnants in hepatic overexpression
of apoE means that chylomicron particles must obtain the
apoE molecules at some point in the pathway through which
they are metabolized in plasma, finally to be taken up by the
liver.
In the study reported here, we directly measured plasma
clearance of '25I-labeled human chylomicrons and compared
the apoE content of chylomicrons and remnants reisolated
from plasma and liver after injection ofchylomicrons. For fur-
ther study of the mechanism by which hepatic overexpression
ofapoE enhances hepatic uptake ofchylomicrons, distribution
of apoE in hepatocytes and changes in its distribution after
injection of lipoproteins were investigated by immunohisto-
chemistry. The data suggested that chylomicrons and their
remnants were enriched with apoE molecules on the surface of
hepatocyte in the sinusoidal space and were immediately endo-
cytosed by hepatic receptors. This local apoE shuttle mecha-
nism was specific for chylomicron remnants and not for he-
patic lipoproteins.
Methods
Materials. Na-'25I and '251I-Protein A were purchased from NEN-Du
Pont (Boston, MA). BSA, PMSF, and Triton X-100 were obtained
from Sigma Chemical Co. (St. Louis, MO)-. All reagents used were of
analytical grade. BDF1 mice were from Nippon Bio-Supp. Inc. (To-
kyo, Japan).
Animals. Transgenic mice, MAE 4-20, which overexpress rat apoE
under the control of the metallothionein promotor, MAE 4-20 were
established as described previously ( 12, 13). Homozygous and hetero-
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zygous line 4-20 aged 16-20 wk were used in this study. Normal mice
with the same genetic background ( C57BL6 X BDA] F2 hybrids) and
ofthe same age were used as controls for MAE 4-20. The animals were
maintained on normal chow and given water supplemented with 20
mM ZnSO4 for > 1 wk to induce the expression of rat apoE from the
transgene. Before intravenous injection oflipoproteins for kinetic stud-
ies and immunohistochemistry, the animals were fasted for 12 h.
Lipoproteins and iodination. Chylomicrons were prepared from
pleural effusion of a patient with malignant lymphoma and chylo-
thorax. VLDL and LDL were prepared from plasma drawn from nor-
molipidemic volunteers. VLDL from a patient with apoE deficiency
was kindly donated by Dr. T. Teramoto (Teikyo University, Tokyo,
Japan). Fresh effusion and plasma samples were separated with diso-
dium EDTA (1 mg/ml), sodium azide (0.2 mg/ml), and benzamidine
(300 ytg/ml).
Chylomicrons were separated by ultracentrifugation at 40,000 rpm
in a rotor (SW28; Beckman Instruments, Inc., Fullerton, CA) for 0.5 h,
followed by reultracentrifugation at 20,000 rpm for 16 h. The composi-
tion was (wt/wt %): total protein 4.8%, triglycerides 77%, phospho-
lipids 6.7%, free cholesterol 3.0%, and cholesterol ester 8.5%. For sepa-
ration of VLDL and LDL, plasma was ultracentrifuged in a 50.2-Ti
rotor at 45,000 rpm at 12°C at KBr densities of 1.006 and 1.063 for 16
and 20 h, respectively ( 15). The floating lipoproteins were reultracen-
trifuged in a 40.3 rotor and dialyzed against 150 mM NaCl, 2 mM
sodium phosphate (pH 7.4), 0.1 mg/ml EDTA, and 0.2 mg/ml so-
dium azide. Chylomicrons and VLDL were iodinated with 1251 by the
method of McFarlane ( 16) with slight modification as previously de-
scribed ( 14).
Kinetic studies. Turnover studies of iodinated chylomicrons and
VLDL were performed as previously described ( 14). For calculation of
chylomicron kinetics, the injected apoB count of tracer per estimated
plasma volume (4.5% of body wt) was taken as 100%. For VLDL ki-
netics, the radioiodine in apoB in plasma prepared 1 min after the
injection was taken as 100% at time 0.
Immunohistochemical procedures for light microscopy. Animals
fasted for 12 h were anesthetized with pentobarbital. Lipoproteins (0.3
mg protein ofchylomicrons orVLDL or 0.5 mg protein ofLDL/ 100 g1
PBS) or saline as a control were injected through the tail vein. 7 min
after injection, the livers were perfused with ice-cold saline through a
portal vein and resected. Small aliquots from the right lobes of the
resected livers were immediately fixed in 4% paraformaldehyde in PBS
(pH. 7.4). Other portions of the samples were used for preparation of
membrane pellets. Paraformaldehyde-fixed, paraffin-embedded sec-
tions were subjected to immunohistochemistry ( 17 ). For apoE immu-
nostaining, two primary antibodies were used: a rabbit anti-rat apoE
polyclonal antibody, which detects both rat and mouse apoE's, and
rabbit polyclonal antibody to rat apoE-specific synthetic oligopeptide,
which does not cross-react with mouse apoE ( 12). Antiserum was di-
luted to 1:200 with PBS. The sections oflivers were incubated with the
respective antibodies overnight. After washing with PBS, the biotiny-
lated second antibodies (goat anti-rabbit IgG antibody) were added.
The sections were visualized by the addition of peroxidase-conjugated
streptavidin.
Analysis ofchylomicron apoE after intravenous injection. Chylomi-
crons (0.3 mg protein) were injected into the tail vein of 12-h fasted
animals. 10 min after injection, blood was drawn by cardiac puncture.
The plasma samples were layered by saline containing 0.01% EDTA,
and chylomicrons and remnants were reisolated by ultracentrifugation
in SW41 at 20,000 rpm for 1 h. The livers were resected after perfusion
with ice-cold saline through the portal vein and liver membrane frac-
tions (8000-100,000 g pellets) were prepared as previously described
(11, 14). Membrane pellets were frozen at -80°C and thawed in PBS
containing 10 mM Suramin. The samples were layered by saline con-
taining 0.01% EDTA and ultracentrifuged at 20,000 rpm for 1 h. The
floating lipoproteins were isolated and subjected to SDS-PAGE.
Electrophoresis and immunoblot. The apoE in chylomicron sam-
ples was separated by polyacrylamide gel electrophoresis in the pres-
ence of SDS as described by Laemmli ( 18 ). Aliquots of the chylomi-
crons containing 100 Mg of triglycerides were dissolved in 50 Ml of 3%
SDS, 62.5 mM Tris-HCl (pH 6.8), 10% glycerol, 0.025% bromophenol
blue, and 5% mercaptoethanol, and heated at 100I C for 3 min. Electro-
phoresis was performed in 11% polyacrylamide slab gels containing 1%
SDS. After electrophoresis, the gel was stained with Coomassie brilliant
blue. In some experiments, the proteins were electrophoretically trans-
ferred to nitrocellulose membranes in the glycine buffer at 200 mA for
8 h. The sheet was incubated with the same buffer containing anti-rat
apoE serum ( 11 ) for 12 h at 4VC, followed by incubation in the buffer
containing '251-Protein A (2,000 cpm/ng, 0.5 Mg/ml) for 2 h at room
temperature. The sheets were washed, air dried, and autoradiographed
on x-ray film.
Results
Kinetics of25I-chylomicrons and 25I VLDL. 125I-labeled chy-
lomicrons were injected intravenously, and plasma clearances
were compared in transgenic mice and control (Fig. 1). Since
the values were calculated from the radioactivities in apoB in
'251-labeled chylomicrons, the data represented plasma clear-
ance ofin terms ofthe number ofparticles. The injected chylo-
microns were much more rapidly cleared in transgenic mice
than in controls. In the first 5 min, 59 and 22% of apoB in
injected chylomicrons were removed in transgenic and control
mice, respectively. In one experiment, livers were resected 10
min after the injection and the total counts in the liver were
measured after extensive perfusion. The total count in the liver
of transgenic mice was 72% of total injected count and was
threefold higher than in control (n = 2). Thus, injected chylo-
microns were taken up primarily by the liver and the rapid
plasma clearance in transgenic mice was attributed mainly to
enhanced hepatic uptake. In contrast, plasma clearance of 125I-
labeled human VLDL was similar in the transgenic and control
mice (Fig. 2 A). This was in striking contrast to our previous
finding that plasma clearance of VLDL prepared from trans-
genic mice, and thus already apoE-rich, was markedly faster in
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Figure 1. Plasma turnover of 125I-labeled human chylomicrons in
apoE transgenic mice. '251-labeled human chylomicrons (1 MCi/ 100
,Ml per animal) was injected into transgenic mice (homozygous MAE
4-20) (0) and controls (0) through the tail vein (n = 3). At designated
intervals after injection, blood samples were drawn from the retroor-
bital vein for determination of plasma radioactivity in apoB by the
isopropanol precipitation method. The increase in the plasma triglyc-
eride level of any sample at 2 min after the injection did not reach
5 mg/dl in any sample. Values are percentages of the injected ra-
dioiodine in apoB remaining in the plasma. Each point represents the
mean±SD (bar).
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Figure 2. Plasma turnover of '25I-labeled human VLDL (A) and
apoE-deficient VLDL (B) in apoE transgenic mice. Human VLDL
and apoE-deficient VLDL were prepared from a normolipidemic
volunteer with the E3/E3 isoform and a patient with apoE deficiency,
respectively. Each VLDL sample was labeled with '25I and injected
(1 tCi/ 100 gl per animal) into transgenic mice (homozygous MAE
4-20) (0) and controls (0) through the tail vein (n = 3). At designated
intervals after injection, blood samples were drawn from the retroor-
bital vein for determination of plasma radioactivity in apoB by the
isopropanol precipitation method. Blood samples obtained 1 min
after injection were taken as time 0. The increase in plasma triglycer-
ide level was not significant in any sample. Values are percentages
of time 0 plasma radioactivity in apoB remaining in blood plasma.
Each point represents the mean±SD (bar).
transgenic mice than that of endogenous VLDL in control
mice ( 14). It is possible that the human VLDL used was suffi-
ciently apoE rich, and that there was no space for additional
incorporation of rat apoE to enhance plasma clearance. To
exclude this possibility, we performed a kinetic study ofVLDL
in the presence ofapoE deficiency. The removal of 125I-VLDL
prepared from apoE-deficient patients was also similar be-
tween the two groups (Fig. 2 B). These data indicated that
hepatic overexpression ofand high plasma level ofapoE had no
effect on plasma clearance of exogenous human VLDL.
Immunohistochemical localization ofapoE in liver oftrans-
genic mice. For determination of the direct involvement of
hepatic overexpression ofapoE in enhanced chylomicron rem-
nant clearance, livers of transgenic mice were immunohisto-
chemically studied with rat apoE-specific antibody. This anti-
body detects only the transgene product, rat apoE, and not
mouse or human apoE ( 13). As shown in Fig. 3 A, marked
immunostaining of apoE was seen at the sinusoidal front in
transgenic mouse liver. The distribution was uniform across
the hepatic lobule, from the portal tracts to the central veins. At
higher magnification (Fig. 3 B), apoE was found peripherally
near the basolateral surface ofevery hepatocyte, while minimal
in the cytoplasm. This result was consistent with apoE localiza-
tion in the liver ofrat as previously reported ( 19). There was no
marked basolateral staining in the liver ofcontrol animal (Fig.
3 C). When control liver was stained with rat apoE polyclonal
antibody cross-reactive with mouse apoE, a similar sinusoidal
pattern was found in hepatocytes of control animals, although
it was less intense than in transgenic mice (Fig. 3, D and E),
indicating that the transgene product and endogenous mouse
apoE were distributed similarly. As a test ofwhether or not the
basolateral hepatic apoE was used for hepatic uptake of chylo-
micron remnants, a large amount ofchylomicron (0.3 mg pro-
tein) was injected intravenously in a bolus and the changes in
apoE distribution were studied. 7 min after the injection of
chylomicrons, the liver was resected and stained. This was the
interval during which 75% of labeled chylomicron was cleared
in the transgenic mice, and thus was estimated to be long
enough for a large quantity ofinjected chylomicron to be taken
up. Sinusoidal immunostaining ofapoE was markedly reduced
as compared to the preinjection level (Fig. 4,A and B). Instead,
immunostaining was observed in a vesicular pattern in the cy-
toplasm. This change in the immunostaining pattern suggests
that in the process of hepatic uptake of large amounts of in-
jected chylomicrons, basolateral apoE was consumed and re-
duced, while endosomes containing apoE-rich lipoproteins ap-
peared in a vesicular pattern in the cytoplasm. In contrast,
injection of VLDL and LDL had no effect on the sinusoidal
staining ofapoE, although slight vesicular staining appeared in
the cytoplasm (Fig. 5, A and B).
Estimation ofapoE content ofchylomicrons and remnants
after intravenous injection of chylomicrons. Enhanced clear-
ance of chylomicron remnants in transgenic mice may be
caused by an increased number ofapoE molecule on the parti-
cles, which would increase their affinity for hepatic receptors.
To estimate the extent of transfer ofapoE to injected chylomi-
cron particles, chylomicron remnants were reisolated from
plasma and liver membrane after injection of chylomicrons,
and subjected to SDS polyacrylamide gel analysis (Fig. 6).
Since the amount of injected chylomicrons would be in excess
of the capacity of lipoprotein lipase in the mouse, these reiso-
lated particles probably contained much unhydrolyzed chylo-
microns, as well as their remnants. Human apoE was observed
in original human chylomicrons used for injection at an appar-
ent molecular mass of 35 kD in doublets, resulting from the
presence of its sialylated form. As shown in Fig. 6 A, chylomi-
crons and remnants reisolated from plasma oftransgenic mice
had a trace amount ofhuman apoE and a small amount of rat
apoE, the transgene product of 34 kD. In contrast, when pre-
pared from the liver membrane fraction after injection, chylo-
microns and remnants from transgenic mice were highly
enriched with rat apoE and contained a markedly higher level
ofapoE than the original particles (Fig. 6 B). These data were
confirmed by immunoblot using rat apoE-specific antibody
(Fig. 7). In transgenic mice, the particles reisolated from liver
membrane were estimated to be fourfold enriched with rat
apoE as compared to those from plasma. As compared to the
injected particles, the contents ofapoC's were grossly increased
in the chylomicrons in plasma and markedly reduced in liver
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Figure 4. Changes in hepatic localization
ofapoE after injection ofchylomicrons
as assessed by immunohistochemistry.
Human chylomicrons (0.3 mg protein/
100 ,d PBS) were injected into transgenic
mice (homozygous MAE 4-20) through
the tail vein. 7 min later, blood was drawn
by cardiac puncture, and the liver was
perfused with ice-cold saline and resected
for immunohistochemistry with anti-rat
apoE-specific antibody. The plasma tri-
glyceride level in blood samples was 300-
400 mg/dl. Representative data from
several experiments are shown. A, x 50;
B, xO0.
membranes (Fig. 6). This suggests that mouse apoC's might be
considerably transferred to chylomicrons and remnants, dis-
place human apoE in plasma, and then be replaced by rat apoE
in the liver. These data suggest that the transfer of apoE to
chylomicrons and remnants occurred mainly after their influx
into the liver rather than while they were in the circulation.
There may be some methodological problems in this experi-
ment. First, chylomicrons and remnants that were reisolated
from plasma 10 min after injection may not reflect the particles
that had been already cleared, especially for apoE content. In
some experiments, blood was drawn after different intervals
such as 1 min and 5 min after the injection. These reisolated
particles contain apoE in amounts different, but consistently
much smaller than the particles respectively reisolated from
liver membrane. Second, apoE-rich VLDL produced in the
liver may contaminate the particles reisolated from liver mem-
brane and cause overestimation of apoE content on remnants
reisolated from liver membrane, although the condition of ul-
tracentrifugation was for chylomicrons and not for VLDL.
When prepared from liver membrane without injection ofchy-
lomicrons, total amount of refloated lipoproteins, which were
considered to be mainly newly synthesized VLDL, was < 5%
(in triglycerides) that of lipoproteins reisolated from liver
membrane after the injection, suggesting that reisolated lipo-
protein after the injection was mainly chylomicrons and rem-
nants. Taken together with the presence ofapoC's in plasma as
Figure 3. Immunohistochemical localization of apoE in liver of transgenic (A, B, and D) and control mice (C and E). Liver samples from
transgenic (homozygous MAE 4-20) and control mice were processed for immunostaining with two polyclonal anti-rat apoE antibodies. The
antibody to purified whole rat apoE, used in D and E, reacts with both rat and mouse apoE. The antibody to rat apoE-specific oligopeptide,
used in A-C, detects only rat apoE. The specificities of these antibodies were previously confirmed by immunoblot analysis of rat and mouse
plasma samples ( 12). A, D, and E, X50; B and C, x100.
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Figure 5. Changes in hepatic localization of apoE after injection ofVLDL (A) and LDL (B) as determined by immunohistochemistry. Human
VLDL and LDL from a normolipidemic volunteer with the apoE3 isoform (0.5 mg protein/ 100 ,d PBS) were injected into transgenic mice
(homozygous MAE 4-20) through the tail vein. 7 min later, blood was drawn by cardiac puncture and the liver was perfused with ice-cold saline
and resected for immunohistochemistry with anti-rat apoE-specific antibody. X50.
a competitor for plasma transfer to chylomicrons and rem-
nants, the main site ofapoE transfer to the particles was consid-
ered to be the sinusoidal space.
Discussion
The data from this kinetic study of 1251-chylomicrons are highly
consistent with the results ofour previous study ( 14), in which
we used oral retinyl palmitate loading as a marker for chylomi-
cron remnant metabolism: in that investigation, plasma levels
of retinyl palmitate after oral administration were fivefold
lower in transgenic mice than in controls. It is now established
that hepatic overexpression of apoE markedly enhances
plasma clearance ofchylomicron remnants. A high apoE con-
tent on chylomicron remnants would be essential to an effi-
cient receptor mediated-endocytosis, although functional prop-
osition of LDL receptors and chylomicron remnant receptors
that might be LRP is controversial ( 19-22). The chylomicrons
used in this study were prepared from pleural effusions of a
patient with chylothorax and were relatively poor in apoE. The
calculated molar ratio of apoE to apoB estimated by turbidity
immunoassay was - 1.3, meaning that, on average, one parti-
cle contains only one apoE molecule. The greater part ofthese
apoE-poor chylomicron particles have low or no affinity for the
hepatic lipoprotein receptors, such as LDL receptors. How-
ever, plasma clearance of these particles was markedly en-
hanced in the transgenic mice, while the plasma clearance of
'25I-labeled VLDL was not enhanced. The mechanism ofapoE
transfer might differ among lipoprotein classes. To gain the
affinity for hepatic receptor, the injected chylomicron particles
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A Plasma Figure 6. SDS-polyacrylamide
orig cont tg gel analysis ofapoE in chylo-
human rat microns and remnants reiso-
apnE apoE lated from plasma and liver
apoAl _ _ after injection ofchylomicrons.
Human chylomicrons were in-
jected into transgenic and con-
trol animals. 10 min after in-
apoCsam_ jection, blood samples were
drawn by cardiac puncture.
B Liver The liver was perfused with
orig cont tg ice-cold saline and resected for
human preparation ofliver membrane
apoE
~ rat pellets. Chylomicrons and
apoAI~apoE remnants were reisolated fromapoAl Om
plasma (A) and liver mem-
brane (B) samples, as de-
scribed in the Methods. Each
sample (100 gg of triglyceride)
apoCsu. from transgenic (tg) and con-
trol (cont) mice and original
chylomicrons (ori) used for the injection were subjected to 11%
SDS-PAGE and stained with Coomassie brilliant blue. Human apoE
and rat apoE in doublets (in unsialylated and sialylated forms) were
detected at apparent molecular mass of 35 and 34 kD, respectively,
which were estimated between markers of 42.7 and 31.0 kD.
must have incorporated rat apoE molecules, which had been
overproduced in the liver, before they were endocytosed. A key
question is whether apoE molecules overexpressed by the liver
were transferred to chylomicron remnants from other apoE-
rich lipoproteins in the plasma or directly from the liver. To
address this question, hepatic localization of apoE should be
investigated.
It was reported that rat apoE molecules are localized at the
basolateral surface of rat hepatocytes on the microvillous ex-
tensions into the space ofDisse ( 19). Our present immunohis-
tochemical data from both transgenic and control mice were
consistent with this. We also confirmed the presence ofapoE in
the liver plasma membrane fraction by immunoblotting using
apoE antibody (data not shown). The reduction in basolateral
liver plasma
31.0 kD
rat
apoE
42.7 kD
Figure 7. Immunoblot
analysis of apoE in chy-
lomicrons and rem-
nants reisolated from
plasma and liver after
injection of chylomi-
crons. Chylomicrons
and remnants were rei-
solated from plasma
(plasma) and liver
membrane (liver) sam-
ples of transgenic mice,
as described in Fig. 6.
Each sample (10 ug of
triglyceride) was sub-
jected to immunoblot
using rat apoE-specific
antibody. Molecular
weight markers are in-
dicated.
apoE density after injection of chylomicron strongly suggests
that hepatic apoE molecules aggregating at the sinusoidal front
of hepatocytes were consumed for apoE enrichment of chylo-
microns and remnants. Hepatic LDL receptors were reported
to be situated at the basolateral surface of hepatocytes (23).
The similar pattern of apoE and LDL receptors suggests that
enrichment of chylomicrons and remnants with apoE may be
immediately followed by hepatic uptake through LDL recep-
tors, since several lines ofevidence indicate that LDL receptors
play a major role in plasma clearance ofchylomicron remnants
in rodents (21, 22, 24). LRP, which is as likely a candidate as
chylomicron remnant receptors, appears to be also similarly
localized and involved in hepatic uptake of chylomicrons and
remnants.
SDS-PAGE analysis of reisolated chylomicrons and rem-
nants after injection of chylomicrons supports that apoE en-
richment may occur mainly in the sinusoidal space and par-
tially in the plasma. ApoC's may be involved in the limited
plasma transfer of apoE to chylomicrons and remnants.
ApoC's are known to inhibit the interaction ofapoE with both
LDL receptor (25) and LRP (26). The competitive transfer of
apoE and apoC's might have resulted in a small but consider-
able amount of rat apoE detected in chylomicrons and rem-
nants reisolated from plasma oftransgenic mice and the almost
undetectable amount of mouse apoE in plasma of control
mice. Considerable plasma apoE transfer to chylomicrons and
remnants may occur only in the transgenic mice with a marked
high plasma apoE level. It has been reported that both apoE
and apoC's were transferred to lymph chylomicrons upon in-
cubation with plasma in rats (27).
These results, even if under unphysiological conditions,
might imply an interesting mechanism oftransport of intestin-
ally absorbed lipids to the liver, presented schematically in Fig.
8, which has been proposed first by Hamilton et al. ( 19) and
later enunciated by others as secretion-recapture theory (28).
Daily food intake results in episodic appearance of intestinal
lipoproteins in the circulation. These intestinal chylomicron
particles are subjected to lipolysis by lipoprotein lipase (LPL)
and probably to competitive transfer ofapoE and apoC's from
other apoE- and apoC-rich lipoproteins. Meanwhile, apoE is
produced continuously in the liver. The apoE molecules, that
escaped incorporation onto nascent VLDL, are stored at the
sinusoidal front ofhepatocytes, ready for the influx ofchylomi-
cron remnants. Postprandially, chylomicron remnants flowing
through the portal vein encounter abundant apoE molecules
on the cell surface of hepatocytes or newly secreted apoE mole-
cules in the sinusoidal space and become highly apoE-rich. It is
also possible that apoE transfer may occur from apoE-rich lipo-
proteins (mainly HDL) to the remnants during their residence
in this space. These events may be associated with replacement
of apoC's on the particles in the competitive way. Subse-
quently, these apoE-rich particles are endocytosed through the
interaction of apoE with hepatic lipoprotein receptors, which
completes secretion-recapture process. If the initial capture of
the remnant particles were mainly by the cell surface apoE, the
rapid plasma clearance of chylomicron remnants are can be
well explained by this initial sequestration in the sinusoidal
space. This system would be very suitable for the removal of
steep episodic and steep influx of intestinal lipoproteins, which
lack apoE, into plasma. The system is specific for chylomicron
remnants and not for hepatic lipoproteins such as VLDL
and LDL.
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Fi8gure 8. Schematic representation of the secretion-
recapture process of apoE for hepatic uptake of chy-
lomicrons and remnants. The means of attachment
of apoE molecules to the cell surface of hepatocytes
and their positional relationship to hepatic lipoprotein
receptors are unknown.
How apoE molecules attach to the cell surface is unknown.
They may bind to hepatic receptors as free apolipoproteins
(19). Alternatively, apoE molecules may be attached to cell
surface heparan sulfate proteoglycans (19, 28), since apoE
avidly binds to proteoglycan (29) and the site of heparan sul-
fate of hepatocytes is similar to those of apoE and LDL recep-
tor (30). Recent reports suggest that cell surface heparan sul-
fate proteoglycans function in cellular uptake of lipoproteins in
vitro (31, 32) and initial sequestration of chylomicron rem-
nants in sinusoidal space from plasma (33). LPL and LRP
have been also proposed to be involved in this process (32, 34).
The precise mechanism for uptake of remnants by hepatocytes
involving apoE, proteoglycans, LPL, LRP, and LDL receptor
is yet to be elucidated.
In the current study, it was demonstrated that hepatic over-
production ofapoE enhances plasma clearance ofchylomicron
remnants, and that hepatic cell surface apoE might play an
important role in the metabolism of these lipoproteins by the
secretion-recapture mechanism. The theory proposed here is
based on rat apoE, the transgene product from the liver of
transgenic mice. The similar distribution ofendogenous mouse
apoE in the liver and a high homology between the two mole-
cules suggest that this theory can be applied to normal mice
and probably to humans.
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